Condition: SCLC,Extensive Stage · SLFN11-positive · Sponsor: ETOP IBCSG Partners Foundation
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
This description comes directly from the study's public registry record.
Heidi Roschitzki, PhD · +41 31 511 94 00 · heidi.roschitzki@etop.ibcsg.org
Susanne Roux · RAISE@etop.ibcsg.org
Always discuss trial participation with your own doctor first.
| CHU - Angers | Angers, France | Recruiting |
| Centre Hospitalier d'Avignon | Avignon, France | Recruiting |
| Caen - CHU | Caen, France | Recruiting |
| Lyon - Centre Léon Bérard | Lyon, France | Not Yet Recruiting |
| LMU Klinikum / Thoracic Oncology center Münich | München, Germany | Recruiting |
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) | Meldola, Italy | Recruiting |
| Instituto Europeo di Oncologia (IEO) | Milan, Italy | Not Yet Recruiting |
| Santa Maria della Misericordia Hospital | Perugia, Italy | Recruiting |
| Complejo Hospitalario Universitario a Coruña | A Coruña, Spain | Not Yet Recruiting |
| Complejo Hospitalario de Jaén | Jaén, Spain | Recruiting |
| Hospital Universitario Puerta de Hierro | Madrid, Spain | Recruiting |
| Kantonsspital Baden | Baden, Switzerland | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05718323